U.S. Markets open in 2 hrs 47 mins

Melanoma: BMY’s Growing Opportunity in Fiscal 2018

Margaret Patrick
Melanoma: BMY’s Growing Opportunity in Fiscal 2018

In Bristol-Myers Squibb’s (BMY) third-quarter earnings conference call, the company estimated the contribution of melanoma indication to Opdivo’s US market revenues to be close to 30%. The contribution is ~20% in ex-US markets. The company expects the contribution of lung cancer indication to Opdivo’s revenues in ex-US markets to gradually decline as the drug penetrates deeper into other newly launched indications. Growth drivers